T 1777/12 (Metabolic disorders/AMYLIN PHARMACEUTICALS) of 02.06.2016
- European Case Law Identifier
- ECLI:EP:BA:2016:T177712.20160602
- Date of decision
- 2 June 2016
- Case number
- T 1777/12
- Petition for review of
- -
- Application number
- 01991093.4
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Peptide PYY[3-36] for treatment of metabolic disorders
- Applicant name
- Amylin Pharmaceuticals, Inc.
- Opponent name
- Glaxo Group Limited
Novo Nordisk A/S (opposition withdrawn) - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2)European Patent Convention Art 123(3)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 83European Patent Convention Art 84European Patent Convention R 115(2)Rules of procedure of the Boards of Appeal Art 15(3)
- Keywords
- Main request - requirements of the EPC met (yes)
- Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The appeal is dismissed